Biora Therapeutics Inc PROG
Dividend Summary
There have not been any declared dividends recently.
Summary | Previous dividend | Next dividend |
---|---|---|
Status | – | – |
Type | – | – |
Per share | – | – |
Declaration date | – | – |
Ex-div date | – | – |
Pay date | – | – |
Enter the number of Biora Therapeutics Inc shares you hold and we'll calculate your dividend payments:
Sign up for Biora Therapeutics Inc and we'll email you the dividend information when they declare.
Add Biora Therapeutics Inc to receive free notifications when they declare their dividends.
Your account is set up to receive Biora Therapeutics Inc notifications.
Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
---|---|---|---|---|---|---|---|---|
There are no Biora Therapeutics Inc dividends. |
Year | Amount | Change |
---|---|---|
2006 | 0.0c | — |
2007 | 0.0c | 0% |
2008 | 0.0c | 0% |
2009 | 0.0c | 0% |
2010 | 0.0c | 0% |
2011 | 0.0c | 0% |
2012 | 0.0c | 0% |
2013 | 0.0c | 0% |
2014 | 0.0c | 0% |
2015 | 0.0c | 0% |
2016 | 0.0c | 0% |
2017 | 0.0c | 0% |
2018 | 0.0c | 0% |
2019 | 0.0c | 0% |
2020 | 0.0c | 0% |
2021 | 0.0c | 0% |
2022 | 0.0c | 0% |
2023 | 0.0c | 0% |
2024 | Sign Up Required |
Biora Therapeutics Inc Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 08 December 2023
- 52 Week Low
- 0.0% on 08 December 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Biora Therapeutics Inc
Biora Therapeutics, Inc., formerly Progenity, Inc., is a biotechnology company focused on developing oral biotherapeutics. It delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United States
- Share Price
- $1.37 (yesterday's closing price)
- Shares in Issue
- 5 million
- Market Cap
- $6mn
- 0
- Market Indices
- none